Nav: Home

Fewer, larger radiotherapy doses prove effective for prostate cancer patients

September 28, 2015

Giving fewer but higher doses of radiotherapy, is as effective at treating prostate cancer as giving lower doses for a longer period, according to new research* presented at the 2015 European Cancer Congress today (Monday).

The results could mean men need fewer trips to hospital - over four weeks rather than seven and a half - without reducing the quality and impact of their prostate cancer treatment.

The Cancer Research UK funded CHHiP trial - the largest randomised treatment trial ever undertaken in localised prostate cancer led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust - gave 3216 men with prostate cancer from across the UK different schedules of radiotherapy.

Some men received standard radiotherapy of 74 Gy** over 37 days (two Gy a day) while others were given either 60 Gy delivered over 20 days or 57 Gy over 19 days (three Gy a day).

The researchers then followed these patients for five years and, overall, found that giving patients 60 Gy over 20 days was as effective as the standard treatment - in terms of both controlling the disease and for long-term side effects.

Some short-term side effects of the higher daily radiotherapy doses during and immediately after radiotherapy were higher than for standard radiotherapy, but these - including bowel and bladder problems - were not long lasting. There was no difference in the side effects after six months or during the next five years.

Lead investigator Professor David Dearnaley, Professor of Uro-Oncology at The Institute of Cancer Research, London, and Consultant at The Royal Marsden, said: "These data are encouraging news for men. Excellent control rates and a low side effect profile have been seen across the trial. Giving patients larger doses of radiotherapy for a shorter time will mean fewer hospital trips and less radiotherapy needed overall. These findings are the result of many years of research and should help to further refine treatment. It appears to be safe and effective and we recommend it as a new standard of care. The study has facilitated the widespread introduction of high quality modern radiotherapy and these advanced techniques are necessary to deliver short high dose treatments safely."

Dr Emma Hall, Deputy Director of the Cancer Research UK-funded Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, which co-ordinated the study, said: "The technique used to give the radiotherapy has led to low levels of side effects even with the higher daily dose. We have also shown that the 20 day schedule is at least as good at controlling disease as the current 37 day schedule. We estimate that over 150,000 trips to hospital could be saved per year".

Around 41,700 men are diagnosed with prostate cancer every year in the UK. More than 10,800 men die from the disease annually. In the UK, radiotherapy is the most commonly used treatment to cure localised prostate cancer.

Professor Malcolm Mason, Cancer Research UK's prostate cancer expert, said: "These results are great news for men. From a logistical and patient convenience point of view, being able to treat patients over a shorter period of time has been a goal for specialists, but the question has always been whether it was safe to do so. This study shows that it is safe and effective, and there should be no reason why this cannot be implemented immediately - it is saving the NHS resources.

"But there are still questions we need answers to. It's not impossible that fewer, but bigger fractions of radiotherapy might be still better at controlling the disease, but this would need more data from large clinical trials to answer. We look forward to seeing more research - perhaps by combining this and similar studies. It's also valuable to see the impact of the shorter treatment on side effects. Reassuringly, these are no different to the older, standard treatment.

"Treating patients in this way means that special attention should be paid to the very best radiotherapy planning, including the need for the most sophisticated equipment and looking at whether newer techniques like intensity modulated radiotherapy - IMRT - might be especially useful in this setting."
For media enquiries contact the Cancer Research UK press office on 020 3469 8300 or, out or hours, on 07050 264 059.

Notes to editor:

* Presidential Session III LATE-BREAKING ABSTRACT 8: 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group

** Gy refers to Gray, the unit by which radiotherapy is measured and delivered to cancer patients.

Earlier results of the CHHiP trial looking at safety can be found here:

About Cancer Research UK
  • Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
  • Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
  • Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
  • Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last forty years.
  • Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that 3 in 4 people will survive their cancer for at least 10 years within the next 20 years.
  • Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
  • Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit Follow us on Twitter and Facebook.

The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes.

Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden NHS Foundation Trust and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.

The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.

The ICR's mission is to make the discoveries that defeat cancer. For more information visit

Cancer Research UK

Related Prostate Cancer Articles:

ASCO and Cancer Care Ontario update guideline on radiation therapy for prostate cancer
The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy (internal radiation) for patients with prostate cancer.
Patient prostate tissue used to create unique model of prostate cancer biology
For the first time, researchers have been able to grow, in a lab, both normal and primary cancerous prostate cells from a patient, and then implant a million of the cancer cells into a mouse to track how the tumor progresses.
Moffitt Cancer Center awarded $3.2 million grant to study bone metastasis in prostate cancer
Moffitt researchers David Basanta, Ph.D., and Conor Lynch, Ph.D., have been awarded a U01 grant to investigate prostate cancer metastasis.
New findings concerning hereditary prostate cancer
For the first time ever, researchers have differentiated the risks of developing indolent or aggressive prostate cancer in men with a family history of the disease.
Prostate cancer discovery may make it easier to kill cancer cells
A newly discovered connection between two common prostate cancer treatments may soon make prostate cancer cells easier to destroy.
More Prostate Cancer News and Prostate Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#534 Bacteria are Coming for Your OJ
What makes breakfast, breakfast? Well, according to every movie and TV show we've ever seen, a big glass of orange juice is basically required. But our morning grapefruit might be in danger. Why? Citrus greening, a bacteria carried by a bug, has infected 90% of the citrus groves in Florida. It's coming for your OJ. We'll talk with University of Maryland plant virologist Anne Simon about ways to stop the citrus killer, and with science writer and journalist Maryn McKenna about why throwing antibiotics at the problem is probably not the solution. Related links: A Review of the Citrus Greening...